Compare Dr. Reddys with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AUROBINDO PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AUROBINDO PHARMA DR. REDDYS LAB/
AUROBINDO PHARMA
 
P/E (TTM) x 21.5 14.7 146.5% View Chart
P/BV x 3.2 3.2 100.9% View Chart
Dividend Yield % 0.7 0.4 186.9%  

Financials

 DR. REDDYS LAB   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
AUROBINDO PHARMA
Mar-18
DR. REDDYS LAB/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,875809 355.4%   
Low Rs1,888504 374.6%   
Sales per share (Unadj.) Rs930.2281.1 331.0%  
Earnings per share (Unadj.) Rs117.441.4 283.9%  
Cash flow per share (Unadj.) Rs185.850.9 365.1%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.80.4 220.5%  
Book value per share (Unadj.) Rs844.4199.4 423.6%  
Shares outstanding (eoy) m166.07585.88 28.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.3 109.6%   
Avg P/E ratio x20.315.9 127.8%  
P/CF ratio (eoy) x12.812.9 99.4%  
Price / Book Value ratio x2.83.3 85.6%  
Dividend payout %17.06.0 281.8%   
Avg Mkt Cap Rs m395,496384,630 102.8%   
No. of employees `00022.017.3 126.7%   
Total wages/salary Rs m33,56221,308 157.5%   
Avg. sales/employee Rs Th7,032.89,500.7 74.0%   
Avg. wages/employee Rs Th1,527.91,229.4 124.3%   
Avg. net profit/employee Rs Th887.71,397.9 63.5%   
INCOME DATA
Net Sales Rs m154,482164,666 93.8%  
Other income Rs m3,3751,020 330.9%   
Total revenues Rs m157,857165,686 95.3%   
Gross profit Rs m31,78237,718 84.3%  
Depreciation Rs m11,3485,580 203.4%   
Interest Rs m889777 114.4%   
Profit before tax Rs m22,92032,380 70.8%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8588,183 47.1%   
Profit after tax Rs m19,50024,229 80.5%  
Gross profit margin %20.622.9 89.8%  
Effective tax rate %16.825.3 66.6%   
Net profit margin %12.614.7 85.8%  
BALANCE SHEET DATA
Current assets Rs m111,101121,878 91.2%   
Current liabilities Rs m58,97386,806 67.9%   
Net working cap to sales %33.721.3 158.4%  
Current ratio x1.91.4 134.2%  
Inventory Days Days79130 61.1%  
Debtors Days Days9468 137.8%  
Net fixed assets Rs m101,24581,037 124.9%   
Share capital Rs m830586 141.7%   
"Free" reserves Rs m139,406116,218 120.0%   
Net worth Rs m140,236116,804 120.1%   
Long term debt Rs m22,0004,512 487.6%   
Total assets Rs m224,656211,052 106.4%  
Interest coverage x26.842.7 62.8%   
Debt to equity ratio x0.20 406.1%  
Sales to assets ratio x0.70.8 88.1%   
Return on assets %9.111.8 76.6%  
Return on equity %13.920.7 67.0%  
Return on capital %14.927.4 54.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67380,727 109.8%   
Fx outflow Rs m19,10434,700 55.1%   
Net fx Rs m69,56946,027 151.1%   
CASH FLOW
From Operations Rs m28,70419,548 146.8%  
From Investments Rs m-7,727-19,570 39.5%  
From Financial Activity Rs m-21,3268,642 -246.8%  
Net Cashflow Rs m-3148,922 -3.5%  

Share Holding

Indian Promoters % 25.5 54.1 47.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.0 67.9%  
FIIs % 35.3 27.7 127.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.2 150.0%  
Shareholders   75,885 69,601 109.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   VENUS REMEDIES  PROCTER & GAMBLE HEALTH  NOVARTIS  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 16, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - TTK HEALTHCARE COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS